AbCellera Biologics has broadened its partnership with Eli Lilly to discover therapeutic antibodies in immunology, cardiovascular disease and neuroscience programmes.
The deal expansion is based on a research collaboration initiated in March 2020 to discover antibodies for up to nine therapeutic targets chosen by Lilly.
Go deeper with GlobalData
The 2020 deal included eight de novo programmes and a sole licence for AbCellera’s Covid-19 antibody programme.
The original agreement between AbCellera and Lilly has seen significant advancements, with all eight programmes progressing effectively.
The collaboration yielded two Covid-19 antibody therapies that received emergency use authorisation from the US Food and Drug Administration.
In the expanded deal, Lilly will hold the rights for the development and commercialisation of any therapeutic antibodies that emerge from the companies’ joint efforts.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn return, AbCellera received an upfront payment. The company is also entitled to receive research payments as well as downstream milestone payments and royalties on the net product sales of successful commercialisation.
AbCellera founder and CEO Carl Hansen stated: “Lilly has been a terrific partner and is one of the most admired and innovative pharmaceutical companies in the world.
“We are excited to deepen our partnership and potentially increase our impact on patients across multiple therapeutic areas.”
In March 2024, AbCellera signed a partnership deal with Biogen for the discovery of therapeutic antibodies for neurological ailments. The companies will execute the discovery and development of antibodies for a new target that will aid in offering brain biotherapeutics for neurological indications.
AbCellera focuses on discovering and creating antibody therapeutics for indications, including cancer, metabolic and endocrine problems, and autoimmune illnesses.
The company’s engine brings together technology, data science, infrastructure and interdisciplinary teams to tackle the most difficult antibody discovery issues.
AbCellera is focused on expanding its own pipeline of first and best-in-class projects, as well as co-operating with partners on new medication development initiatives.
